Creative Medical Technology Secures FDA Clearance
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leading name in biotechnology focusing on regenerative medicine, recently achieved a significant milestone by securing FDA clearance for an expanded dose escalation in its ongoing clinical trial of CELZ-201-DDT. This innovative therapy targets chronic lower back pain, primarily stemming from degenerative disc disease (DDD). The FDA's endorsement was driven by promising interim results that highlighted remarkable pain reduction and enhanced mobility for trial participants.
Overview of the Clinical Trial
The trial employs a cutting-edge, minimally invasive technique involving ultrasound-guided injections of CELZ-201-DDT in an outpatient setting. This first-of-its-kind study operates on a treatment-to-placebo ratio of 4:1, which has allowed researchers to gather robust data on the therapy's impact. With the completion of half the trial, the findings point towards a favorable safety profile, reporting no dose-limiting toxicities or serious adverse events. This critical information bolsters the case for CELZ-201-DDT as a viable alternative in chronic pain management.
Key Findings and Implications
One of the standout features of the trial is the endorsement from both the Data Safety Monitoring Board (DSMB) and the Institutional Review Board (IRB), which have approved the updated dosing strategy. The FDA's clearance to expand the dosage means the opportunity to further refine treatment protocols and optimize therapeutic outcomes for patients suffering from DDD.
Ongoing Trial Milestones
Throughout the duration of the study, several key milestones have been noted:
- Safety Profile: Zero serious adverse events reported during the first half of the trial, emphasizing the therapeutic safety.
- Efficacy Signals: Interim data shows substantial pain relief and improved mobility compared to baseline measurements.
- FDA Clearance for Expansion: The recently obtained FDA clearance enhances the potential for optimizing treatment strategies.
- Trial Enrollment: Enrollment continues as planned, with expectations for final data to inform the direction of future clinical and regulatory initiatives.
Future Prospects for CELZ-201-DDT
“The positive findings we've seen reinforce our belief in CELZ-201-DDT as a potential breakthrough non-opioid solution for chronic back pain,” stated Timothy Warbington, President and CEO of Creative Medical Technology Holdings. He emphasized that FDA clearance signifies a pivotal advancement in their journey to enhance both safety and effectiveness. Should the favorable data continue, there is optimistic speculation regarding an accelerated path towards a Phase 3 trial and eventual submission for a Biologics License Application (BLA).
Creative Medical Technology's Mission and Products
Creative Medical Technology Holdings is staunchly committed to bringing forth regenerative medicine innovations. Their mission revolves around addressing critical unmet needs within the realms of pain management and tissue regeneration, leveraging next-generation cell therapy technologies.
About CELZ-201-DDT
Designed to address the root causes of DDD, CELZ-201-DDT is an allogeneic regenerative therapy that is delivered through ultrasound-guided injection. This approach is minimally invasive and aims to reduce patient discomfort while enhancing functionality and tissue health. Unlike traditional cell therapies, this method avoids exposing patients to radiation, marking a significant advancement in treatment methodologies.
About the Company
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a pioneering clinical-stage biotechnology company specializing in regenerative medicine solutions across various medical specialties, including pain management, neurology, and urology. By employing advanced cell therapy technologies, the company is dedicated to improving patient outcomes and fostering transformative treatments.
Contact Information
For additional inquiries, Creative Medical Technology Holdings, Inc. can be reached at IR@CreativeMedicalTechnology.com. For investor relations, please contact Devin Sullivan, Managing Director at The Equity Group Inc. at dsullivan@equityny.com, or Conor Rodriguez, Associate at crodriguez@equityny.com.
Frequently Asked Questions
What is CELZ-201-DDT?
CELZ-201-DDT is an innovative allogeneic regenerative therapy aimed at alleviating chronic lower back pain due to degenerative disc disease.
What does FDA clearance for expansive dosing mean?
The FDA clearance allows for modifications in the dosing strategy, potentially improving treatment efficacy for patients in the clinical trial.
How is CELZ-201-DDT administered?
This therapy is administered through a minimally invasive ultrasound-guided injection, allowing for outpatient treatment without the need for invasive surgical procedures.
What safety measures are in place for the trial?
The trial implements strict monitoring from both the Data Safety Monitoring Board and Institutional Review Board, ensuring participant safety throughout the process.
What are the future prospects for CELZ-201-DDT?
If ongoing data trends remain positive, it may expedite the pathway towards pivotal Phase 3 trials and potential Biologics License Application submission to the FDA.
